Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The Stock for 1999(Polymedica)PLMD(Medical Supply Co.) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (3072)	6/13/2000 6:18:00 PM
From: rob g	Read Replies (1) \| Respond to of 3414

that research certainly sounds promising but i can't see how it could tremendously impact the market. the first hurdle to cross is the pathetically small number of organ donors. transplant docs would need to harvest the intact donor organ and then perform that pancreatic cell liberating procedure. then after infusing them into the patient, the only way to keep the patient from rejecting the newly implanted cells would be to keep the patient immunocompromised for the rest of his life unless they find a better way to do this. the insulin business should thrive for years to come unless something earthshattering is developed. for all the suffering diabetics out there, i hope this happens but for now i think polymedica will continue to grow.